Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Ottawa

$105,000.00

Development of a broadly protective mRNA vaccine for Lyme disease

FY 2023-24

Summary
Lyme disease (LD) is the most common illness transmitted by ticks in North America. In 2021, over 3,000 cases of LD were reported in Canada alone. In fact, the number of LD cases is rapidly increasing due to the northern migration of black-legged ticks. LD is caused by the bacteria, Borrelia burgdorferi, which produces skin lesions and flu-like symptoms in infected individuals. If left untreated, the infection can result in more severe symptoms, including arthritis, heart conditions, and neurological disorders. Notably, the only licensed vaccine for LD was removed from the market in 2001, leaving no vaccine available for the prevention of LD in humans. In this study, I propose the development of an mRNA vaccine that protects against multiple strains of Lyme disease. To test the efficacy of this vaccine, two doses will be administered to mice prior to infection with one of five B. burgdorferi strains commonly found in Canada. I will then quantify the number of antibodies produced in response to vaccination and measure the amount of bacteria in several mouse tissues. I will also perform in-depth analysis of the immune response to vaccination to better understand the mechanisms underlying protection. Overall, this project will help determine whether an mRNA vaccine could provide protection against multiple strains of LD. Given the increasing incidence of LD and the severity of the disease, this research is fundamentally important to the health of Canadians.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
497342
Name
Pfeifle Annabelle
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of a broadly protective mRNA vaccine for Lyme disease
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Antibodies; Antibody Effector Functions; Broad-Spectrum Protection; Cellular And Humoral Immune Responses; Immunology; Lipid Nanoparticles; Lyme Disease; Mrna Vaccine; Polyvalent Vaccine; Tick-Borne Illness
Abstract
Lyme disease (LD) is the most common illness transmitted by ticks in North America. In 2021, over 3,000 cases of LD were reported in Canada alone. In fact, the number of LD cases is rapidly increasing due to the northern migration of black-legged ticks. LD is caused by the bacteria, Borrelia burgdorferi, which produces skin lesions and flu-like symptoms in infected individuals. If left untreated, the infection can result in more severe symptoms, including arthritis, heart conditions, and neurological disorders. Notably, the only licensed vaccine for LD was removed from the market in 2001, leaving no vaccine available for the prevention of LD in humans. In this study, I propose the development of an mRNA vaccine that protects against multiple strains of Lyme disease. To test the efficacy of this vaccine, two doses will be administered to mice prior to infection with one of five B. burgdorferi strains commonly found in Canada. I will then quantify the number of antibodies produced in response to vaccination and measure the amount of bacteria in several mouse tissues. I will also perform in-depth analysis of the immune response to vaccination to better understand the mechanisms underlying protection. Overall, this project will help determine whether an mRNA vaccine could provide protection against multiple strains of LD. Given the increasing incidence of LD and the severity of the disease, this research is fundamentally important to the health of Canadians.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Pfeifle, Annabelle
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~